Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management

被引：44

作者：

Savoia, Paola ^{[1
,2
]}

Astrua, Chiara ^{[1
]}

Fava, Paolo ^{[1
]}

机构：

[1] Univ Turin, Dept Med Sci, Turin, Italy

[2] A Avogadro Univ Eastern Piedmont, Dept Hlth Sci, Novara, Italy

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期

关键词：

anti-CTL-A4; ipilimumab; immunotherapy; melanoma treatment; toxicity; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; T-CELL RESPONSES; RECOMBINANT INTERLEUKIN-2 THERAPY; PRETREATED ADVANCED MELANOMA; EXPANDED ACCESS PROGRAM; CTLA-4; BLOCKADE; BRAIN METASTASES; PHASE-2; TRIAL; ADVERSE EVENTS; DOUBLE-BLIND;

D O I：

10.1080/21645515.2015.1129478

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.

引用

页码：1092 / 1101

页数：10

共 50 条

[1] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma [J].

Lipson, Evan J. ;

Drake, Charles G. .

CLINICAL CANCER RESEARCH, 2011, 17 (22) :6958-6962

[2] Anti-CTLA-4 antibodies A major therapeutic advance in metastatic melanoma treatment [J].

Robert, Caroline ;

Mateus, Christine .

M S-MEDECINE SCIENCES, 2011, 27 (10) :850-858

[3] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy [J].

Bowyer, S. ;

Prithviraj, P. ;

Lorigan, P. ;

Larkin, J. ;

McArthur, G. ;

Atkinson, V. ;

Millward, M. ;

Khou, M. ;

Diem, S. ;

Ramanujam, S. ;

Kong, B. ;

Liniker, E. ;

Guminski, A. ;

Parente, P. ;

Andrews, M. C. ;

Parakh, S. ;

Cebon, J. ;

Long, G. V. ;

Carlino, M. S. ;

Klein, O. .

BRITISH JOURNAL OF CANCER, 2016, 114 (10) :1084-1089

[4] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy [J].

S Bowyer ;

P Prithviraj ;

P Lorigan ;

J Larkin ;

G McArthur ;

V Atkinson ;

M Millward ;

M Khou ;

S Diem ;

S Ramanujam ;

B Kong ;

E Liniker ;

A Guminski ;

P Parente ;

M C Andrews ;

S Parakh ;

J Cebon ;

G V Long ;

M S Carlino ;

O Klein .

British Journal of Cancer, 2016, 114 :1084-1089

[5] The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network [J].

Voskens, Caroline J. ;

Goldinger, Simone M. ;

Loquai, Carmen ;

Robert, Caroline ;

Kaehler, Katharina C. ;

Berking, Carola ;

Bergmann, Tanja ;

Bockmeyer, Clemens L. ;

Eigentler, Thomas ;

Fluck, Michael ;

Garbe, Claus ;

Gutzmer, Ralf ;

Grabbe, Stephan ;

Hauschild, Axel ;

Hein, Ruediger ;

Hundorfean, Gheorghe ;

Justich, Armin ;

Keller, Ullrich ;

Klein, Christina ;

Mateus, Christine ;

Mohr, Peter ;

Paetzold, Sylvie ;

Satzger, Imke ;

Schadendorf, Dirk ;

Schlaeppi, Marc ;

Schuler, Gerold ;

Schuler-Thurner, Beatrice ;

Trefzer, Uwe ;

Ulrich, Jens ;

Vaubel, Julia ;

von Moos, Roger ;

Weder, Patrik ;

Wilhelm, Tabea ;

Goeppner, Daniela ;

Dummer, Reinhard ;

Heinzerling, Lucie M. .

PLOS ONE, 2013, 8 (01)

[6] Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody) [J].

Akhtari, Mojtaba ;

Waller, Edmund K. ;

Jaye, David L. ;

Lawson, David H. ;

Ibrahim, Ramy ;

Papadopoulos, Nicholas E. ;

Arellano, Martha L. .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (03) :322-324

[7] Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma [J].

Sarnaik, Amod A. ;

Weber, Jeffrey S. .

CANCER JOURNAL, 2009, 15 (03) :169-173

[8] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma [J].

Kaehler, Katharina C. ;

Hassel, Jessica C. ;

Heinzerling, Lucie ;

Loquai, Carmen ;

Moessner, Rotraut ;

Ugurel, Selma ;

Zimmer, Lisa ;

Gutzmer, Ralf .

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07) :662-681

[9] Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings [J].

Lens, Marko ;

Ferrucci, Pier F. ;

Testori, Alessandro .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2008, 3 (02) :105-113

[10] Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1 [J].

Simeone, Ester ;

Ascierto, Paolo A. .

JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (03) :241-247

← 1 2 3 4 5 →